According to one embodiment of the present invention, provided is a drug-clay mineral complex, in which the complex comprises a phospholipid, and the drug has an amine group.

The present invention provides isolated nanosheets each of which includes a plurality of pseudo-polyrotaxanes and which are easily isolated without adhering to each other. The present invention provides an isolated nanosheet including a plurality of pseudo-polyrotaxanes each having one or more first cyclic molecules and a linear molecule included in a cavity or cavities of the first cyclic molecules in a skewered manner, wherein the linear molecules include, as part thereof, first linear molecules each having an ionizable group that ionizes in water or an aqueous solution.

Disclosed is a self-assembled complex containing copper ions, including: copper ions; and one or more ligands, in which the ligands and the copper ions are reversibly self-assembled or self-degraded, and when there are a plurality of types of ligands or a plurality of ligands, the shape of the self-assembled complex is formed differently depending on the blending ratio of the ligands.

Disclosed is a method for preparing supramolecular cell-based carrier, which relates to the technical fields of supramolecular chemistry, supramolecular materials and cell preparations. Host-guest interactions mediated supramolecular cell-based carriers can achieve targeted delivery based on cell physiological functions, and have high biocompatibility, physiological barrier permeability, and targeting delivery efficiency. It does not require covalent bond modification on the cell surface, and has no effect on the physiological functions of transporting cells. The preparation method of supramolecular cell-based carrier provided by the present application has the advantages of simple and fast construction process, mild conditions and universal applicability, and the method has bio-orthogonality. In addition, a drug loading system is also provided, which can realize drug loading for targeted therapy.

Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by α-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.

The present invention provides antibody-payload conjugates having a payload-to-antibody ratio of 1. The antibody-payload conjugate having structure (1): wherein: a, b and c are each independently 0 or 1; L.sup.1, L.sup.2 and L.sup.3 are linkers; D is a payload; BM is a branching moiety; Z are connecting groups obtainable by a cycloaddition reaction.

The invention further provides a method for preparing the antibody-payload conjugate according to the invention, an intermediate compound in that preparation method, and medical uses of the antibody-payload conjugate according to the invention.

Described herein are polyhedral, three-dimensional tunable nanocages assembled with a multimeric protein covalently linked to a polynucleotide handle and a DNA origami base assembly including sequences complementary to the polynucleotide handles, wherein the polynucleotide handle and the complementary sequences hybridize to for double-stranded DNA helices.

Disclosed herein, are Zwitterion polymer conjugates. The conjugate comprises a Zwitterion polymer, a linker, and a therapeutic polypeptide. Also described herein, are compositions comprising the conjugates, methods of their preparation, methods of treating diseases with the conjugates or their compositions, and method of preventing aggregation of therapeutic proteins.

The present invention relates to a method for preparing a DNA network with a controlled crystal structure and a method for injecting drugs using the DNA network, and more specifically, the present invention relates to a method for controlling crystallinity in a DNA network by controlling the content of DTT relative to magnesium chloride in a process of synthesizing a functional DNA network by amplifying a circular DNA loaded with a functional base sequence through rolling circle amplification. Further, the present invention provides the possibility of applying pH-sensitive drug-controlled-release during injection by loading an anticancer drug into the DNA network prepared above.

An antimicrobial composition of buckminsterfullerene with gallium phosphonate functional groups is provided to disassemble or make virus particles inert, and to inhibit viral and fungal proteases using catalytic desulfurization. This composition prevents and inactivates novel corona viruses including variant strains of SARS-Cov-2, fungal pathologies such as valley fever, respiratory ailments such as chronic obstructive pulmonary disorder (COPD), pneumonia, and arthropod vectored bacterial pathogens such as Lyme disease. The antiviral properties further prevent conditions leading to uncontrolled cellular proliferation, neoplasms, degenerative malignancy, cancers, and chronic inflammatory diseases. The gallium similarity to iron permits the treatment of osteoporosis, hypertension, and thrombosis by depolymerizing fibrin in the dissolution of clots and restoration of vascular plasticity. The composition can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, inhalation, or injection when used as a medicament or as a food supplement.